The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | Myeloma CAR-T update with Nina Shah
Nina Shah, MD, of the University of California, San Francisco, CA, discusses the advent of BCMA CAR-T therapy in multiple myeloma, highlighting data from the KarMMA trial (NCT03361748), updates with ciltacabtagene autoleucel (cilta-cel), and orvacabtagene autoleucel (orva-cel; NCT03430011). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
